CD8A and cancer: Specifically, SABR could facilitate the immunogenic cell death of cancer cells, release tumor antigens, recruit antigen-presenting cells to present antigens to T cells, and activate the antitumor effect of CD8+ T cells through TCR and CD28 signals [38].